Hemcheck's Newsletter - August 2021

Welcome to the August Newsletter from Hemcheck

We are back at full speed at Hemcheck after the summer vacation period in July. We have in August welcomed two new colleagues and we are full of energy with many activities planned and ongoing. We look forward to the autumn and the potential opportunities that are ahead of us.

In this newsletter you can read about our interview with BioStock, some of our commercial developments and an interview with the new CTO of Hemcheck.

Looking ahead, the main focus for our work during the autumn will be to bring all the new team members up to speed, continue the commercialisation efforts focusing on customer trials, new paying customers and distributors. We will also have a clear focus on finalising the CE-marking process for the new product we are developing for the blood gas market.

Enjoy the reading!
Joen Averstad, CEO

Hemcheck CEO interviewed by BioStock

Hemcheck CEO Joen Averstad has been interviewed by BioStock.

Link to the interview

Evaluation agreement transferred into distribution agreement - Turkish market

Hemcheck Sweden AB and Hemakim Tibbi Ürünler San.Ve Tic. A.S (”Hemakim”) has agreed to continue the collaboration into a distribution agreement regarding the Turkish market valid until the end of May 2023. The market research and tests performed during the evaluation period have all turned out well. The next steps taking place now are trials with several hospitals to create concrete interest in adopting the technology.

Read more
hemakim logo

Hemcheck receives order from a British distributor

Hemcheck Sweden AB has received an evaluation order from a British distributor. The order is of minor economic value but validates the interest that exists in the British market, which is a very interesting market. We are in several discussions and e.g. trials in Liverpool as earlier communicated, hence we hope we can take additional steps in the UK market during the Autumn.

Read more

Evaluation agreement signed regarding distribution in Denmark

Hemcheck Sweden AB has signed a 4-month evaluation agreement with potential continuation into a 24-month long distribution agreement with Hettich Labinstrument ApS (”Hettich”), regarding the Danish market. Hettich is one of the leading distributors of medical equipment in Denmark.
The agreement is formed to evaluate a potential collaboration, and Hettich has committed to an initial purchase order of readers and one-time tests for a value of 8,000 EUR, should the agreement be extended after the evaluation period.

Read more

Meet the new CTO of Hemcheck

Hemcheck has during the spring welcomed David Melin as the new CTO for the company. David came from the position of Director Product Development at SciBase, where he had been for 8 years. He has also held several positions within the area of product development before. Below you can read more about his priorities and focus areas for the future at Hemcheck.

Can you tell our readers a little more about yourself, David?

I have a background in mechanical engineering, focusing on electronics, mechanics and software development. I have previously worked as a consultant before entering the Medtech Area at SciBase. There, I started out as a hardware developer which then led me to the position as manager for the Product Development department. This has given me a broad exposure and competence within the product development field. Now, I look forward to driving the product development at Hemcheck, which will likely cover a broad range of topics, which is how I like my work to be.

What is your first impression so far, a few months into your new position at Hemcheck?

It is very exciting to enter the world of blood sampling and analysis. Many things are new to me and I am looking forward to continuing learning more. It is also good to see the widespread interest in our technology. Both in the intended area of usage, but also in new ways that our potential customers come up with, which we evaluate on a case by case basis.

What are the most important priorities for you looking forward?

The first priority is to complete the CE-marking of our new product for the blood gas market. We have come a long way, but some work still remains to be done. Apart from this, my priorities will be to continue to optimize our existing products and to expand our offer to reach an even wider audience in the market.
Since many are new in the company, we will also prioritise building the team together. All in all it should be an exciting autumn!

Hemcheck_logo_line_preview 2

Upcoming events 2021

August 24th

September 6th
POCT: Making the point

Contact Us
Hemcheck Sweden AB
Karlstads universitet
Universitetsgatan 2
651 88 Karlstad